Impact of glycaemic and lipid control on outcome after percutaneous coronary interventions in diabetic patients

Open Access
Publisher Website
Google Scholar
Abstract
From January 2000 to June 2001, 280 consecutive patients with type 2 diabetes mellitus successfully underwent their first elective PCI at one of our institutions. Optimal metabolic control was defined as a glycosylated haemoglobin (HbA1c) concentration of < 7.0% and a low density lipoprotein cholesterol (LDL-C) concentration < 100 mg/d (< 2.6 mmol/l). Three groups were identified: (1) optimal group (n = 45, 16% of patients) with optimal glycaemic and lipid control; (2) suboptimal group (n = 126, 45% of patients) with only one target value reached; (3) poorly controlled group (n = 109, 39% of patients) who failed to reach either glycaemic or lipid target values. The end point of the study was the rate of major adverse cardiovascular events (MACE), defined as death of any cause, non-fatal myocardial infarction, and target vessel revascularisation, at 12 months in the three groups of patients. All patients received aspirin (325 mg daily, indefinitely) and ticlopidine (250 mg twice daily, for at least 30 days) or clopidogrel (75 mg daily, for at least 30 days). Glycoprotein IIb/IIIa inhibitors were administered according to operator discretion.